Belgium (BE)

BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer (2017) Shimelis H, Mesman RLS, Von Nicolai C, Ehlen A, Guidugli L, Martin C, Calleja FMGR, et al. Journal article Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci (2017) Glubb DM, Johnatty SE, Quinn MCJ, O'Mara TA, Tyrer JP, Gao B, Fasching P, et al. Journal article TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer (2017) Fagerholm R, Khan S, Schmidt MK, Garcia-Closas M, Heikkila P, Saarela J, Beesley J, et al. Journal article Impact of combined sodium chloride and saturated long-chain fatty acid challenge on the differentiation of T helper cells in neuroinflammation (2017) Hammer A, Schliep A, Joerg S, Haghikia A, Gold R, Kleinewietfeld M, Mueller DN, Linker R Journal article STRUCTURAL DAMAGE PROGRESSION IN PATIENTS TREATED WITH METHOTREXATE, BARICITINIB MONOTHERAPY OR BARICITINIB plus METHOTREXATE BASED ON THEIR LEVEL OF CLINICAL RESPONSE IN THE PHASE 3 RA-BEGIN STUDY (2017) Van Der Heijde D, Durez P, Schett G, Naredo E, Ostergaard M, Meszaros G, Bello N, et al. Conference contribution SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 3-YEAR EFFICACY AND SAFETY RESULTS FROM PHASE 3 FUTURE 1 TRIAL (2017) Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Conference contribution SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS (PSA) THROUGH 3 YEARS: EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL (2017) Hall S, Mease P, Kavanaugh A, Reimold A, Tahir H, Rech J, Geusens P, et al. Conference contribution OPTIMAL DOSE OF TOCILIZUMAB FOR THE TREATMENT OF GIANT CELL ARTERITIS: EFFICACY, SAFETY, AND EXPOSURE-EFFICACY ANALYSIS FROM GIACTA (2017) Stone JH, Tuckwell K, Dimonaco S, Klearman M, Mallalieu NL, Aringer M, Blockmans D, et al. Conference contribution Baseline characteristics of Crohn's disease patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (02) (2017) Siegel CA, Lichtenstein G, Siegmund B, Lewis JD, Wolf D, Louis E, Sebastian S, et al. Conference contribution Exploratory Analysis to Identify Factors Associated with Risk of Structural Progression, Defined As Change from Baseline (2017) Van Der Heijde D, Durez P, Schett G, Naredo E, Ostergaard M, Meszaros G, Lopez-Romero P, et al. Conference contribution